“We reviewed letters over 18 months sent to violating companies by the FDA. Cannabidiol-related substances led the spectrum of products with unsubstantiated claims to treat COVID-19 infection.”
Tag: cannabidiol
A three judge panel for the Ninth Circuit Court of Appeals has denied a petition filed by the Hemp Industries Association challenging the DEA’s authority to establish a new administrative drug code specifically for marijuana extracts. Petitioners say that will appeal the ruling.
The daily administration of CBD (cannabidiol) as an adjunctive therapy mitigates psychotic symptoms in patients with schizophrenia, according to clinical trial data published online ahead of print in The American Journal of Psychiatry.
The use of the naturally occurring cannabinoid CBD (cannabidiol) possesses no likely abuse potential and therefore should not be subject to international drug scheduling restrictions, according to recommendations finalized today by the World Health Organization’s Expert Committee on Drug Dependence.
The use of the naturally occurring cannabinoid CBD is safe, well tolerated, and is not associated with any significant adverse public health effects, according to the findings of a preliminary report compiled by the World Health Organization’s Expert Committee on Drug Dependence. The agency is in the process of considering whether to place CBD within the agency’s international drug scheduling code.
The US Drug Enforcement Administration has publicly reiterated its position that cannabidiol, a non-psychotropic cannabinoid, is properly categorized under federal law as a schedule I controlled substance — meaning that, by definition, it possesses “a high potential for abuse,” “no currently accepted medical use in treatment in the United States,” and lacks “accepted safety … under medical supervision.”
Oral CBD administration is associated with reduced blood pressure in healthy volunteers, according to clinical trial data published online in the Journal of Clinical Investigation.